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Abstract
Purpose In adults and children, transsphenoidal surgery (TSS) represents the cornerstone of management for most large or 
functioning sellar lesions with the exception of prolactinomas. Endocrine evaluation and management are an essential part 
of perioperative care. However, the details of endocrine assessment and care are not universally agreed upon.
Methods To build consensus on the endocrine evaluation and management of adults undergoing TSS, a Delphi process 
was used. Thirty-five statements were developed by the Pituitary Society’s Education Committee. Fifty-five pituitary endo-
crinologists, all members of the Pituitary Society, were invited to participate in two Delphi rounds and rate their extent of 
agreement with statements pertaining to perioperative endocrine evaluation and management, using a Likert-type scale. 
Anonymized data on the proportion of panelists’ agreeing with each item were summarized. A list of items that achieved 
consensus, based on predefined criteria, was tabulated.
Results Strong consensus (≥ 80% of panelists rating their agreement as 6–7 on a scale from 1 to 7) was achieved for 68.6% 
(24/35) items. If less strict agreement criteria were applied (ratings 5–7 on the Likert-type scale), consensus was achieved 
for 88% (31/35) items.
Conclusions We achieved consensus on a large majority of items pertaining to perioperative endocrine evaluation and man-
agement using a Delphi process. This provides an international real-world clinical perspective from an expert group and 
facilitates a framework for future guideline development. Some of the items for which consensus was not reached, including 
the assessment of immediate postoperative remission in acromegaly or Cushing’s disease, represent areas where further 
research is needed.
Keywords Delphi process · Pituitary adenoma · Transsphenoidal surgery · Hypopituitarism · Perioperative · Postoperative 
assessment
Introduction
Pituitary adenomas are common benign sellar masses and 
account for approximately 90% of sellar lesions in surgical 
case series [1–4]. In addition to pituitary adenomas, a large 
variety of other pathologic entities may occur in the sella. 
Transsphenoidal surgery is the cornerstone of management 
for large non-functioning sellar lesions as well as most non-
prolactinoma functioning tumors.
Endocrine evaluation is essential in patients undergo-
ing transsphenoidal surgery. Society guidelines have been 
published regarding the evaluation and management of 
non-functioning and functioning pituitary tumors [5–12]. 
Nicholas A Tritos and Pouneh K. Fazeli are First authors, and Task 
force co-chairs.
Members of the study group “Pituitary Society Delphi 
Collaborative Group” are listed in Acknowledgements.
 * Mark Gurnell 
 mg299@medschl.cam.ac.uk
 * Maria Fleseriu 
 fleseriu@ohsu.edu
Extended author information available on the last page of the article
 Pituitary
1 3
However, there are still considerable uncertainties regard-
ing the optimal endocrine assessment and management of 
these patients.
The Delphi process has been used with the goal of achiev-
ing consensus among experts from different countries on a 
variety of health-related topics using an iterative process, 
during which anonymized opinions from experts are fed 
back to the same expert panel in a series of rounds [13, 14].
In the present study, we sought to engage pituitary endo-
crinologists towards achieving consensus regarding the 
endocrine evaluation and management of patients undergo-
ing TSS using a Delphi process.
Methods
A Steering Committee, composed of members of the Pitui-
tary Society Education Committee, developed the study 
objectives and the statement questions (please find state-
ment questions summarized in Table 1). References from the 
literature were compiled. A total of 55 endocrinologists from 
5 continents (Asia, Europe, North America, Oceania, South 
America), all members of the international Pituitary Society, 
were invited to participate in the Delphi process via elec-
tronic mail. Ethics approval was not required (the study did 
not enroll any patients and does not report on patient data).
First Delphi round
Delphi panel members were provided with an electronic link 
to the online questionnaire. For each item, the panelists were 
asked to rate their agreement or disagreement on a Likert-
type scale as follows: 1 (“complete disagreement”), 2 (“some 
disagreement”), 3 (“disagreement”), 4 (“neither disagree-
ment nor agreement”), 5 (“agreement”), 6 (“some agree-
ment”) to 7 (“complete agreement”). Panel members were 
allowed to skip any questions they did not wish to answer. 
In addition, panelists were provided with the opportunity 
to suggest additional questions or make comments. Panel 
members were given 4 weeks to complete the survey, and 
a single reminder was sent to those who did not respond. 
Of 55 invited panelists, 50 responded in the first round. 
Anonymized data from the first round were summarized 
and sent to all participants. In addition, several questions 
were modified and additional questions were added by the 
research team, based on comments and suggestions made by 
panel members in the first round.
Second Delphi round
Panel members were recontacted via electronic mail and 51 
of the originally invited panelists participated in the second 
round. Anonymized feedback, showing the distribution of 
panelists’ agreement with each item from the first round, was 
provided to all Delphi panel members in the second round.
Panelists were then asked to rate their agreement with 
each item using the same Likert-type scale used in the first 
round. Questions that had reached strong consensus (defined 
as ≥ 80% of participants rating their agreement as ≥ 6 or ≤ 2 
on the Likert-type scale) during the first round were not 
included in the second Delphi round. Instructions given to 
panel members were otherwise identical to those provided 
during the first Delphi round.
A virtual meeting was originally conceived as a means 
of building further consensus in a modified Delphi process. 
However, consensus was achieved for the majority of items 
by the end of the second round, with only modest changes in 
agreement among panelists between the two rounds of Del-
phi. Due to COVID-19 restrictions and strenuous demands 
on healthcare professionals in many of the countries repre-
sented in the Delphi panel, a virtual meeting after the second 
round of Delphi was not convened.
Data analysis
The proportion of panelist consensus across each item was 
tabulated based on predefined criteria (a response of ≥ 6 sig-
nified agreement and ≤ 2 signified disagreement with state-
ment). The proportion of items that reached consensus was 
tabulated, as was the proportion of statements that achieved 
consensus after question modification.
Results
Thirty-five items pertaining to the preoperative and postop-
erative endocrine evaluation and management of patients 
with sellar masses undergoing transsphenoidal surgery were 
prepared by the Steering Committee. These items were sub-
sequently submitted to the Delphi panel for consideration, 
including two items that were introduced in the second 
round of Delphi in response to feedback from panelists at 
the end of the first round.
The proportion of Delphi panelists that indicated some or 
complete agreement with each item (rating 6 or 7 on a Lik-
ert-type scale) is shown for each of the two rounds of Delphi 
(Table 1). A high proportion of panelists (range 46–51 of 51 
participants) provided ratings for individual items. Using our 
prespecified criteria (≥ 80% of panelists rating their agree-
ment as ≥ 6 or ≤ 2 on the Likert-type scale), consensus was 
achieved for 24 of 35 items (68.6%) at the end of the second 
Delphi round, including three items for which consensus 
was reached after modification or addition of questions for 
the second round.
There was general agreement amongst panelists with 
respect to preoperative evaluation of pituitary function, with 
Pituitary 
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Table 1  Proportion of panelists indicating some or complete agreement (rating 6 or 7 on a Likert-type scale) with individual items pertaining to 
the evaluation and management of adult patients undergoing transsphenoidal surgery
Item number Item First Delphi round Second Delphi round
1 Patients with an apparent pituitary adenoma should have 
serum prolactin measured preoperatively
49/50 (98%) Consensus achieved in Round 1
2 Patients with an apparent macroadenoma and minimally 
elevated prolactin levels should have serum prolactin 
measured in serial dilution preoperatively
31/50 (62%) 36/51 (70.6%)
3 Serum IGF-I should be measured in all patients with a 
sellar mass preoperatively
43/50 (86%) Consensus achieved in Round 1
4 Patients with a macroadenoma or other large (≥ 1 cm) 
sellar mass should undergo evaluation for hypoad-
renalism preoperatively
43/50 (86%) Consensus achieved in Round 1
5 Patients with a sellar mass who present with symptoms 
or signs suggestive of hypoadrenalism should undergo 
evaluation of adrenal reserve preoperatively regardless 
of lesion size
43/50 (86%) Consensus achieved in Round 1
6 All patients with an apparent pituitary adenoma and any 
symptoms or signs of hypercortisolemia should be 
evaluated for Cushing’s disease preoperatively
48/50 (96%) Consensus achieved in Round 1
7 Thyroid function should be tested in all patients with a 
sellar mass preoperatively
42/50 (84%) Consensus achieved in Round 1
8 Evaluation of gonadal function is advisable in patients 
with symptoms suggestive of hypogonadism, those 
with a large (≥ 1 cm) sellar mass and those with a 
functioning tumor regardless of size preoperatively
44/50 (88%) Consensus achieved in Round 1
9 Evaluation of possible diabetes insipidus is advisable in 
patients with a sellar mass who present with polyuria 
and/or hypernatremia preoperatively
45/50 (90%) Consensus achieved in Round 1
10 Patients with hypoadrenalism should receive glucocorti-
coid replacement preoperatively
48/49 (97.9%) Consensus achieved in Round 1
11 Patients with hypothyroidism should receive thyroid 
hormone replacement preoperatively
40/50 (80%) Consensus achieved in Round 1
12 Sex steroid replacement is advisable in symptomatic 
patients with central hypogonadism preoperatively
9/50 (18%) 9/45 (20%)
12a Sex steroid replacement may be considered in sympto-
matic patients with central hypogonadism preopera-
tively
Question 12 modification for Round 2 27/51 (52.9%)
13 Preoperative medical therapy should be considered in 
patients with somatotropin-secreting adenomas
7/50 (14%) 8/46 (17.4%)
13a Preoperative medical therapy may be considered in 
patients with somatotropin-secreting adenomas
Question 13 modification for Round 2 32/50 (64%)
14 Preoperative medical therapy should be considered in 
patients with corticotropin-secreting adenomas
13/50 (26%) 15/47 (31.9%)
14a Preoperative medical therapy may be considered in 
patients with corticotropin-secreting adenomas
Question 14 modification for Round 2 37/51 (72.5%)
15 Stress dose glucocorticoid administration is advisable 
perioperatively
27/50 (54%) 26/49 (53.1%)
15a Stress dose glucocorticoid administration is generally 
advisable perioperatively in patients with known or 
suspected adrenal insufficiency
Question 15 modification for Round 2 48/50 (96%)
16 Serum sodium should be monitored postoperatively 47/50 (94%) Consensus achieved in Round 1
17 Morning serum cortisol should be monitored postopera-
tively (during an interval of 1–5 days postoperatively)
41/50 (82%) Consensus achieved in Round 1
18 Full evaluation of pituitary function should be con-
ducted 6–12 weeks after transsphenoidal surgery
46/49 (93.9%) Consensus achieved in Round 1
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Table 1  (continued)
Item number Item First Delphi round Second Delphi round
19 Serum prolactin should be measured postoperatively (on 
postoperative day 1 or 2) in patients with presumed 
prolactin-secreting adenomas to evaluate for remission
27/49 (55.1%) 27/47 (57.4%)
19a Serum prolactin may be measured postoperatively (on 
postoperative day 1 or 2) in patients with presumed 
prolactin-secreting adenomas to evaluate for remission
Question 19 modification for Round 2 38/51 (74.5%)
20 Dynamic testing should be obtained to evaluate the 
pituitary adrenal axis at 6–12 weeks postoperatively, 
if morning serum cortisol is not sufficiently high to 
assure sufficient adrenal function early postoperatively
43/49 (87.7%) Consensus achieved in Round 1
21 Thyroid function should be assessed in all patients post-
operatively (at 6–8 weeks)
46/49 (93.9%) Consensus achieved in Round 1
22 Gonadal function should be evaluated in patients 
(6–12 weeks) postoperatively, including women of 
premenopausal age and men
44/49 (89.8%) Consensus achieved in Round 1
23 Dynamic testing should be obtained to assess GH secre-
tion postoperatively in patients with clinical suspicion 
of GH deficiency
34/49 (69.4%) 31/46 (67.4%)
23a Dynamic testing may be obtained to assess GH secretion 
postoperatively in patients with clinical suspicion of 
GH deficiency
Question 23 modification for Round 2 43/51 (84.3%)
24 In patients with acromegaly, morning serum GH should 
be obtained early postoperatively (postoperative day 1 
or 2) to evaluate endocrine remission
22/48 (45.8%) 24/48 (50%)
24a In patients with acromegaly, morning serum GH may be 
obtained early postoperatively (postoperative day 1 or 
2) to evaluate endocrine remission
Question 24 modification for Round 2 36/50 (72%)
25 Serum IGF-I should be obtained to evaluate endocrine 
remission at 6 weeks postoperatively. If elevated, 
serum IGF-I should be rechecked at 12 weeks postop-
eratively to document persistent disease activity before 
making treatment decisions
39/48 (81.1%) Consensus achieved in Round 1
26 A glucose tolerance test should be obtained to evalu-
ate endocrine remission of acromegaly several weeks 
postoperatively
26/49 (53.1%) 30/47 (63.8%)
26a A glucose tolerance test may be obtained to evaluate 
endocrine remission of acromegaly several weeks 
postoperatively
Question 26 modification for Round 2 37/51 (72.5%)
27 Patients with acromegaly who are in endocrine remis-
sion should be evaluated biochemically for recurrence 
annually (or sooner if clinically indicated)
43/49 (87.7%) Consensus achieved in Round 1
28 In patients with Cushing’s disease, endocrine testing 
should be conducted during the first postoperative 
week to document endocrine remission
41/48 (85.4%) Consensus achieved in Round 1
29 In patients with Cushing’s disease, serum cortisol 
should be monitored to document endocrine remission 
postoperatively
44/48 (91.7%) Consensus achieved in Round 1
30 In patients with Cushing’s disease, monitoring of 
plasma ACTH levels should be considered to docu-
ment endocrine remission postoperatively
21/48 (43.7%) 14/47 (29.8%)
30a In patients with Cushing’s disease, monitoring of 
plasma ACTH levels may be considered to document 
endocrine remission postoperatively
Question 30 modification for Round 2 32/51 (62.7%)
31 In patients with Cushing’s disease, 24 h urinary free 
cortisol should be monitored to document endocrine 
remission postoperatively
19/48 (39.6%) 25/48 (52%)
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consensus achieved for 8 of 9 items (88.9%). On the other 
hand, there was less agreement amongst panelists regard-
ing preoperative therapy [3 of 6 items (50%)]. Regarding 
postoperative endocrine evaluation, consensus was achieved 
for 12 of 19 items (63.2%). Consensus was also reached on 
the single item on postoperative therapy (1 of 1 item). Items 
for which consensus was reached are summarized in Box 1.
Using predefined criteria on panelists’ extent of agree-
ment (Box 2), consensus was not achieved for 11 items 
after two rounds of Delphi. If using less stringent criteria 
of agreement (i.e., ratings of ≥ 5 on the Likert-type scale), 
similar to other Delphi panels [13, 15], consensus would be 
reached for 88% of items (31 of 35 items, Box 2).
Discussion
In this study, a Delphi process was used towards building 
consensus on endocrine aspects of perioperative evaluation 
and management of adults undergoing transsphenoidal sur-
gery [1, 2].
After two rounds of Delphi, panelists from Asia, 
Europe, North America, Oceania, and South America 
reached consensus on the majority of items submitted to 
them by the research team. There was wide agreement 
on the extent of preoperative and postoperative endocrine 
testing. Despite some uncertainties in previous guidelines 
[16], a clear consensus was achieved in this group to meas-
ure serum IGF-I in all pituitary tumors preoperatively to 
ensure proper diagnosis of GH excess. This is important 
because patients with GH-secreting adenomas do not 
always present with classic manifestations of acromegaly, 
require additional evaluation for comorbidities and may 
benefit from further medical therapy [17].
There was agreement on preoperative administration 
of glucocorticoid and thyroid hormone replacement in 
patients with diagnosed deficiencies as well as periopera-
tive use of stress-dose glucocorticoid coverage for patients 
with known or suspected hypoadrenalism, but not for all 
patients undergoing transsphenoidal surgery. The panelists 
also agreed on postoperative monitoring of serum sodium 
and cortisol and the use of desmopressin “on demand” 
(as required to control hypernatremia and/or polyuria) for 
patients with central diabetes insipidus. Agreement was 
achieved on postoperative monitoring of endocrine func-
tion, including morning serum cortisol in patients with 
Cushing’s disease, as well as serum IGF-I in patients with 
acromegaly.
Regular monitoring of serum sodium levels is important 
and advised for approximately 7–10 days postoperatively, 
including after hospital discharge. This will detect the pos-
sibility of hyponatremia, which could be as high as 20%, 
with symptomatic cases in just 5% of these patients or more 
rarely, a trend for triphasic response. These items are broadly 
consistent with several published guidelines [5–7, 18] and 
highlight the importance of guideline practicability, even 
when the level of evidence per se is limited in real-world 
scenarios.
Table 1  (continued)
Item number Item First Delphi round Second Delphi round
31a In patients with Cushing’s disease, 24 h urinary free 
cortisol may be monitored to document endocrine 
remission postoperatively
Question 31 modification for Round 2 40/51 (78.4%)
32 In patients with Cushing’s disease, late night salivary 
cortisol should be monitored to document endocrine 
remission postoperatively
25/48 (52.1%) 30/47 (63.8%)
32a In patients with Cushing’s disease, late night salivary 
cortisol may be monitored to document endocrine 
remission postoperatively
Question 32 modification for Round 2 38/51 (74.5%)
33 Patients with Cushing’s disease who are in endocrine 
remission should be evaluated for recurrence annually 
(or sooner if clinically indicated)
45/48 (93.7%) Consensus achieved in Round 1
34 Patients with an apparent clinically non-functioning 
pituitary adenoma may be evaluated for Cushing’s 
disease preoperatively
Question added for Round 2 32/46 (69.6%)
35 Desmopressin may be administered “on demand” (as 
required) in patients who underwent transsphenoidal 
surgery and developed central diabetes insipidus in the 
postoperative period
Question added for Round 2 42/51 (82.3%)
Questions 12a, 13a, 14a, 15a, 19a, 23a, 24a, 26a, 30a, 31a, 32a represent modifications of the corresponding original questions and were intro-
duced during the second Delphi round in response to feedback from panelists at the end of the first round of Delphi. The last 2 questions (34 and 
35) were added to the second Delphi round, based on suggestions from panel members
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On the other hand, there were several items for which 
consensus was not achieved by the Delphi panel, using our 
strict, predefined criteria. This at least partly reflects those 
topics where there are either no data available or where there 
is controversy in the literature and more research is needed.
Notably, panelists did not broadly agree on the need to 
measure serum prolactin in dilution in patients with mac-
roadenomas. Prolactin immunoassays can be suscepti-
ble to the “hook effect” artifact, which may lead to sub-
stantial underreporting of prolactin measurements in sera 
containing very high prolactin concentrations [19, 20]. 
Although rare, this artifact can lead to misclassification of 
a prolactin-secreting adenoma as a non-functioning lesion, 
thus having important implications for patient management. 
Some panelists commented that they would recommend 
measuring prolactin in dilution only in sera from patients 
with giant adenomas, while others noted that their labora-
tory routinely tests for deviations from linearity of measured 
prolactin, using automated assay platforms (data not shown). 
While newer automated immunoassay platforms are likely 
to detect the “hook effect”, this may not be the case in older 
assays, which are still in use in many countries. Therefore, 
there is potential for misdiagnosis [21, 22], especially when 
surgery is performed at an institution where automated 
Box 1  Consensus on the evaluation and management of patients undergoing transsphenoidal surgery
Item
Preoperative evaluation of pituitary function
Patients with an apparent pituitary adenoma should have serum prolactin measured preoperatively
Serum IGF-I should be measured in all patients with a sellar mass preoperatively
Patients with a macroadenoma or other large (≥ 1 cm) sellar mass should undergo evaluation for hypoadrenalism preoperatively
Patients with a sellar mass who present with symptoms or signs suggestive of hypoadrenalism should undergo evaluation of adrenal reserve 
preoperatively regardless of lesion size
All patients with an apparent pituitary adenoma and any symptoms or signs of hypercortisolemia should be evaluated for Cushing’s disease 
preoperatively
Thyroid function should be tested in all patients with a sellar mass preoperatively
Evaluation of gonadal function is advisable in patients with symptoms suggestive of hypogonadism, those with a large (≥ 1 cm) sellar mass 
and those with a functioning tumor regardless of size preoperatively
Evaluation of possible diabetes insipidus is advisable in patients with a sellar mass who present with polyuria and/or hypernatremia preopera-
tively
Preoperative hormone replacement
Patients with hypoadrenalism should receive glucocorticoid replacement preoperatively
Patients with hypothyroidism should receive thyroid hormone replacement preoperatively
Stress dose glucocorticoid administration is generally advisable perioperatively in patients with known or suspected adrenal insufficiency
Postoperative endocrine evaluation
Serum sodium should be monitored postoperatively
Morning serum cortisol should be monitored postoperatively (during an interval of 1–5 days postoperatively)
Full evaluation of pituitary function should be conducted 6–12 weeks after transsphenoidal surgery
Dynamic testing should be obtained to evaluate the pituitary adrenal axis at 6–12 weeks postoperatively, if morning serum cortisol is not suf-
ficiently high to assure sufficient adrenal function early postoperatively
Thyroid function should be assessed in all patients postoperatively (at 6–8 weeks)
Gonadal function should be evaluated in patients (6–12 weeks) postoperatively, including women of premenopausal age and men
Dynamic testing may be obtained to assess GH secretion postoperatively in patients with clinical suspicion of GH deficiency
Patients with acromegaly
Serum IGF-I should be obtained to evaluate endocrine remission at 6 weeks postoperatively. If elevated, serum IGF-I should be rechecked at 
12 weeks postoperatively to document persistent disease activity before making treatment decisions
Patients in endocrine remission should be evaluated biochemically for recurrence annually (or sooner if clinically indicated)
Patients with Cushing’s disease
Endocrine testing should be conducted during the first postoperative week to document endocrine remission
Serum cortisol should be monitored to document endocrine remission postoperatively
Patients in endocrine remission should be evaluated for recurrence annually (or sooner if clinically indicated)
Postoperative hormone replacement
Desmopressin may be administered “on demand” (as required) in patients who underwent transsphenoidal surgery and developed central 
diabetes insipidus in the postoperative period
Pituitary 
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assays are available to detect hook effect, yet patient workup 
has been carried out at an outside laboratory that does not 
use such technologies [23]. This scenario can occur more 
often with the widespread use of telemedicine, including 
both distance visits and endocrine testing being carried out 
at a distant laboratory. Careful communication between the 
clinician and laboratory staff is advised to minimize this 
possibility.
There was also lack of consensus regarding preoperative 
testing for hypercortisolism in all patients with an appar-
ently non-functioning pituitary adenoma. This might reflect 
concern about false positive results of endocrine testing in 
some individuals. On the other hand, published data sug-
gest that some patients with Cushing’s disease may lack 
typical symptoms and signs, and can present with an inci-
dentally found sellar mass [24]. These patients are at risk 
of developing severe hypoadrenalism postoperatively if 
glucocorticoid replacement is not instituted. In addition, 
silent corticotropinomas cannot be reliably diagnosed in the 
absence of preoperative testing for hypercortisolism [25, 26]. 
Such patients seem to have a worse prognosis [27, 28].
Preoperative sex steroid replacement was not agreed 
upon, even in symptomatic patients with hypogonadism. 
Some panelists raised concerns that sex steroid administra-
tion carries a prothrombotic risk, which may be even higher 
in the perioperative period (data not shown) [29]. There are 
no data suggesting a better surgical outcome if sex steroids 
are replaced preoperatively.
Items concerning the administration of preoperative 
medical therapy in patients with acromegaly or Cushing’s 
disease did not reach consensus, potentially reflecting dif-
ferences in practice among international centers (including 
Box 2  Items that did not achieve consensus after two rounds of the Delphi process
*Consensus (≥ 80%) would be achieved on these items if responses from panelists with any extent of agreement (ratings 5, 6, 7 on the Likert-
type scale) were considered
Item
Preoperative evaluation of pituitary function
Patients with an apparent macroadenoma and minimally elevated prolactin levels should have serum prolactin measured in serial dilution 
preoperatively
*Patients with an apparent clinically non-functioning pituitary adenoma may be evaluated for Cushing’s disease preoperatively
Preoperative endocrine therapy
Sex steroid replacement is advisable in symptomatic patients with central hypogonadism preoperatively
Sex steroid replacement may be considered in symptomatic patients with central hypogonadism preoperatively
Preoperative medical therapy should be considered in patients with somatotropin-secreting adenomas
*Preoperative medical therapy may be considered in patients with somatotropin-secreting adenomas
Preoperative medical therapy should be considered in patients with corticotropin-secreting adenomas
*Preoperative medical therapy may be considered in patients with corticotropin-secreting adenomas
Stress dose glucocorticoid administration is advisable perioperatively
Postoperative endocrine evaluation
Patients with prolactinomas
 Serum prolactin should be measured postoperatively (on postoperative day 1 or 2) to evaluate for remission
 *Serum prolactin may be measured postoperatively (on postoperative day 1 or 2) to evaluate for remission
All patients
 Dynamic testing should be obtained to assess GH secretion postoperatively in patients with clinical suspicion of GH deficiency
Patients with acromegaly
 Morning serum GH should be obtained early postoperatively (postoperative day 1 or 2) to evaluate endocrine remission
 Morning serum GH may be obtained early postoperatively (postoperative day 1 or 2) to evaluate endocrine remission
 A glucose tolerance test should be obtained to evaluate endocrine remission several weeks postoperatively
 *A glucose tolerance test may be obtained to evaluate endocrine remission several weeks postoperatively
Patients with Cushing’s disease
 Monitoring of plasma ACTH levels should be considered to document endocrine remission postoperatively
 Monitoring of plasma ACTH levels may be considered to document endocrine remission postoperatively
 24 h urinary free cortisol should be monitored to document endocrine remission postoperatively
 *24 h urinary free cortisol may be monitored to document endocrine remission postoperatively
 Late night salivary cortisol should be monitored to document endocrine remission postoperatively
 *Late night salivary cortisol may be monitored to document endocrine remission postoperatively
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various waiting times between diagnosis and transsphenoidal 
surgery among different centers), the clinical heterogeneity 
of patient populations, and ongoing uncertainties regarding 
the benefits of preoperative medical therapy [30–32]. Clini-
cal experience suggests that preoperative medical therapy 
may be helpful in patients with Cushing’s disease and very 
high cortisol levels who present with acute psychiatric ill-
ness or sepsis.
Interestingly, despite substantial work in this area, the 
definition of remission in all hyperfunctioning pituitary 
tumors remains controversial, including the role of imme-
diate postoperative laboratory testing [10, 12]. Several items 
pertaining to the postoperative assessment of remission in 
patients with functioning tumors did not achieve consensus, 
including early prolactin or growth hormone (GH) meas-
urements in patients with prolactinomas or acromegaly, 
respectively, and subsequent post-glucose GH testing in 
acromegaly, or the measurements of plasma adrenocortico-
tropic hormone, 24-h urinary free cortisol, and late-night 
salivary cortisol in Cushing’s disease. These observations 
may partly reflect differences in practice among centers 
or perhaps lack of clinician confidence with regards to the 
accuracy of some endocrine assays. Some data support the 
predictive value of these tests in assessing endocrine remis-
sion [33–36]. Additional research would be helpful to inform 
expert opinion and clinical practice pertaining to assessment 
of endocrine remission.
Strengths of the present study include the relatively large 
size of the Delphi panel, the inclusion of panel members 
from an international pool of experts from five continents, 
including a majority from institutions fulfilling criteria for 
Pituitary Centers of excellence [37], and the very high pro-
portion of panelists who engaged effectively in the Delphi 
process by rating each item. The present report represents 
real-life experience, reflecting variations in the approach to 
endocrine management in different parts of the world among 
diverse healthcare systems and varying financial resources.
In conclusion, substantial consensus on endocrine aspects 
of the perioperative evaluation and management of adults 
undergoing transsphenoidal surgery was reached, using a 
Delphi process. However, consensus was not reached on a 
minority of items, some of which represent areas where fur-
ther research is needed to inform expert opinion, pituitary 
care and further consensus guidelines.
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